Novacyt S.A. (NVYTF)
OTCMKTS
· Delayed Price · Currency is USD
0.617
-0.001 (-0.21%)
At close: Dec 23, 2024
Novacyt Company Description
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa.
It operates through Primer Design, and Yourgene Health segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases.
The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine.
The company was incorporated in 2006 and is based in Le Vésinet, France.
Novacyt S.A.
| Country | France |
| Founded | 2006 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 237 |
| CEO | Lyn Rees |
Contact Details
Address: 131 Boulevard Carnot Le Vésinet, 78110 France | |
| Phone | 44 2380 748830 |
| Website | novacyt.com |
Stock Details
| Ticker Symbol | NVYTF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | FR0010397232 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Lyn Dafydd Rees | Chief Executive Officer and Executive Director |
| Steve Gibson | Chief Financial Officer and Director |
| Bryan Close | Chief Operations Officer |
| Dr. Joanne Mason | Chief Scientific Officer and Director |
| David Franks | Chief Human Resources Officer |
| Paul Oladimeji | Group Head of Research & Development |